



CIC - Centre d'investigation clinique des Quinze-Vingts

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. CIC - Centre d'investigation clinique des Quinze-Vingts. 2018, Institut national de la santé et de la recherche médicale - INSERM, Centre national de la recherche scientifique - CNRS, Université Pierre et Marie Curie - UPMC. hceres-02031871

HAL Id: hceres-02031871

<https://hal-hceres.archives-ouvertes.fr/hceres-02031871>

Submitted on 20 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Research evaluation

REPORT ON THE CIC:
CIC QUINZE-VINGTS

UNDER THE SUPERVISION OF THE
FOLLOWING INSTITUTIONS AND
RESEARCH BODIES:

Institut National de la Santé et de la Recherche
Médicale – INSERM

Centre National de la Recherche Scientifique –
CNRS

Université Pierre et Marie Curie

EVALUATION CAMPAIGN 2017-2018
GROUP D



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the expert committee²:

Gilles Thuret, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the CIC's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

CIC PRESENTATION

name:	CIC QUINZE-VINGTS
number:	1423
Requested label:	
Application type:	Renewal
Head of the CIC (2017-2018):	Mr José Alain SAHEL
Project leader (2019-2023):	Mr José Alain SAHEL
Number of modules or themes:	2

COMMITTEE MEMBERS

Chair:	Mr Gilles THURET, CHU de Saint-Etienne
Experts:	Mr Carl ARNDT, CHU de Reims Mr Philippe KESTELYN, Ghent University, Belgium Mr Maher SALEH, CHU de Besançon Mr Jérôme de SEZE, CHU et CIC de Strasbourg
HCERES scientific officer:	Mr Gilles DEFER
Representatives of supervising institutions and bodies:	Ms Samia DEGHMOUN, INSERM Mr Romain DUVERNOIS, DGA 15-20 Ms Helene ESPEROU, INSERM Mr Nicolas HINCELIN, DGOS

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE CIC

The CIC-OPH is the only CIC solely dedicated to ophthalmology.

Created in 2004 with the desire to link very logically to the Centre Hospitalier National d'Ophtalmologie (CHNO) des 15-20 and the Institut de la Vision (IdV) with a dedicated Clinical Research platform (CRPt) from now on) to implement translational research based on IdV discoveries, attract industrialists, and focused cohorts of patients. The Adolph de Rothschild Foundation's (ARF) Clinical Research (CR) department, with a more paediatric, neuro-ophthalmological and low vision rehabilitation orientation, is historically also associated with the CIC.

The CIC was renewed in 2008 and evaluated A+ by AERES in 2013.

The CIC is located in the "15-20" buildings, for the most part on 3 levels: clinical retina, retinal imaging, glaucoma and surface (clinical and imaging). The AF Foundation's CR department is always associated with it.

The links to the IdV, which is just a few steps away, are close.

It also includes 2 platforms located at the IdV, of virtual reality adapted to visual pathologies unique in France, street lab and homelab, (two systems using virtual reality for visual deficiency) that complete the whole.

MANAGEMENT MODULE

The CIC-OPH is directed since its creation by Mr José Alain SAHEL.

HCERES NOMENCLATURE

SVE6 Santé Publique, Épidémiologie, Recherche Clinique.

SCIENTIFIC DOMAIN

All areas of ophthalmology (excluding cancer) are represented, with a preponderance of retinal diseases (degenerative, dystrophic, vascular) due to the CIC history and the large cohorts of patients with rare retinal pathologies ("genetic dystrophies") but also frequent (AMD, CRVO, uveitis). The CIC has 2 axes largely interconnected:

- a Multi-thematic axis able to include patients in all areas of ophthalmology (Mr Saddek MOHAND-SAID);
- an Innovation Imaging axis (Mr Michel PAQUES). Clinical trials are carried out to validate specific developments in imaging and state-of-the-art imaging is also used during clinical trials of the multi-thematic module.

The share of innovative technological development is preponderant in all areas.

CIC WORKFORCE

CIC workforce	Number 30/06/2017	Number 01/01/2019
Permanent staff		
Full professors, assistant professors and similar positions	8	8
Clinicians (PH)	10	10

Full time research directors (Directeurs de recherche) or Research associates (chargés de recherche) EPST , EPIC and similar positions	0	0
Full professors, associate professors and clinicians (PH) affiliated to a CNRS, INSERM or EA research CIC	0	0
Other permanent staff involved in research: health professionals, supporting personnel etc.	16	14
TOTAL permanent staff	34	32
Non-permanent staff		
Non-permanent professors and associate professors, including emeritus,)	1	
Non-permanent full time scientists, including emeritus, post-docs	3	
Non-permanent supporting personnel	36	
PhD Students	1	
TOTAL non-permanent staff	41	
TOTAL CIC		
	75	

GLOBAL ASSESSMENT OF THE CIC

The CIC-OPH offers a complete ophthalmologic clinical investigation platform.

Several entry modes are possible: The CIC is able to build a clinical trial from A to Z (from design to finalization) carrying out the translation of an academic innovation of 15-20 or IdV but is also offering industrial services.

This flexibility is clearly a strength.

The ability to attract major ophthalmology companies in the field is an undeniable strength and guarantees significant financing.

Its activities are based on highly experienced teams with leaders having each a dominant position in their subspecialty.

There is a major ability of the CIC team to get or be associated with Inserm research units focused on the field of OPH to regularly obtain very high levels of public funding (PHRC, RHU, ANR, ANR industrial chair, ERC,...).

International collaborations are numerous and in very innovative technological fields (retinal prosthesis, gene therapy (USA), ocular surface/Glaucoma (Beijin) for instance), which positions CIC-OPH at the top of the international competition.

The evaluation reports of Hceres
are available online: www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)